Paper15664401
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice.
Yamamoto K and 7 others. Cardiovasc Res, 2005. Cited by 45 papers, by iCite.
Cite this record
ConductScience Library. Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Papers, record 15664401. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15664401
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aorta | Major topic |
| Graft Occlusion, Vascular | Major topic |
| Tenascin | Major topic |
| Tunica Intima | Major topic |
| Actins | |
| Animals | |
| Blood Vessel Prosthesis | |
| Cell Division | |
| Cell Movement | |
| Female | |
| Hyperplasia | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Transgenic | |
| Proliferating Cell Nuclear Antigen | |
| Sutures | |
| Tunica Media |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41617709 | Tenascin C+ myofibroblasts exacerbate vascular neointimal hyperplasia by propagation of nerve-macrophage interactions in mice. | Nat Commun | 2026 | https://conductscience.org/library/papers/41617709 | PubMed |
| 41349733 | Smooth muscle cell phenotypic modulation during atherosclerosis. | Vascul Pharmacol | 2026 | https://conductscience.org/library/papers/41349733 | PubMed |
| 40247455 | Sustained tenascin-C expression drives neointimal hyperplasia and promotes aortocaval fistula failure. | Am J Physiol Heart Circ Physiol | 2025 | https://conductscience.org/library/papers/40247455 | PubMed |
| 38903966 | Biomechanical dysregulation of SGK-1 dependent aortic pathologic markers in hypertension. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/38903966 | PubMed |
| 38339104 | Bioactive TNIIIA2 Sequence in Tenascin-C Is Responsible for Macrophage Foam Cell Transformation; Potential of FNIII14 Peptide Derived from Fibronectin in Suppression of Atherosclerotic Plaque Formation. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38339104 | PubMed |
| 36078128 | The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway. | Cells | 2022 | https://conductscience.org/library/papers/36078128 | PubMed |
| 35941419 | Tenascin-C as a noninvasive biomarker of coronary artery disease. | Mol Biol Rep | 2022 | https://conductscience.org/library/papers/35941419 | PubMed |
| 35203297 | Role of Integrins in Modulating Smooth Muscle Cell Plasticity and Vascular Remodeling: From Expression to Therapeutic Implications. | Cells | 2022 | https://conductscience.org/library/papers/35203297 | PubMed |
| 30116408 | Multiple Roles of Tenascins in Homeostasis and Pathophysiology of Aorta. | Ann Vasc Dis | 2018 | https://conductscience.org/library/papers/30116408 | PubMed |
| 29385356 | Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity. | J Histochem Cytochem | 2018 | https://conductscience.org/library/papers/29385356 | PubMed |
| 28935038 | Bone Marrow-Derived Tenascin-C Attenuates Cardiac Hypertrophy by Controlling Inflammation. | J Am Coll Cardiol | 2017 | https://conductscience.org/library/papers/28935038 | PubMed |
| 28246700 | Integrin signaling in atherosclerosis. | Cell Mol Life Sci | 2017 | https://conductscience.org/library/papers/28246700 | PubMed |
| 26763408 | Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization. | Adv Drug Deliv Rev | 2016 | https://conductscience.org/library/papers/26763408 | PubMed |
| 24939607 | Gellan sulfate core platinum coil with tenascin-C promotes intra-aneurysmal organization in rats. | Transl Stroke Res | 2014 | https://conductscience.org/library/papers/24939607 | PubMed |
| 23656926 | Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall. | Interact Cardiovasc Thorac Surg | 2013 | https://conductscience.org/library/papers/23656926 | PubMed |
| 23433402 | Tenascin-C deficiency in apo E-/- mouse increases eotaxin levels: implications for atherosclerosis. | Atherosclerosis | 2013 | https://conductscience.org/library/papers/23433402 | PubMed |
| 23250985 | Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. | Circ Res | 2013 | https://conductscience.org/library/papers/23250985 | PubMed |
| 23204105 | Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. | Circulation | 2013 | https://conductscience.org/library/papers/23204105 | PubMed |
| 22300502 | Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice. | Cardiovasc Pathol | 2012 | https://conductscience.org/library/papers/22300502 | PubMed |
| 21818551 | Advances in tenascin-C biology. | Cell Mol Life Sci | 2011 | https://conductscience.org/library/papers/21818551 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/15664401
GET https://conductscience.org/api/papers/v1/15664401/cited_by?page=2